Core Viewpoint - WeDoctor Holdings Limited is progressing with its IPO application on the Hong Kong Stock Exchange, having updated its prospectus and disclosed its latest performance up to June 30, 2025, marking its third attempt to go public [1] Business Overview - WeDoctor primarily operates in two core business areas: AI medical services and online-offline medical services. The AI medical services rely on a bundled payment model based on contracted personnel, while the online-offline medical services have evolved from a free online appointment system to a comprehensive healthcare service for individuals and corporate clients [2] Financial Performance - The company has experienced significant revenue growth from 2022 to 2024, with a remarkable increase of 195.1% in 2024 compared to 2023. However, it has faced continuous net losses, with a net loss rate of 30.5% in 2024. The losses are attributed to increased fair value losses on financial instruments issued to investors and rising costs during business expansion [3][6] - In the first half of 2025, the company achieved a revenue of 3.08 billion RMB, a year-on-year increase of 69.4%. The adjusted loss rate from ongoing operations narrowed from 7.0% in the same period last year to 4.2%, indicating a move towards breakeven, and the operating cash flow turned positive for the first time [3] Profitability Metrics - The company's gross margin has shown volatility across its business segments. The health management membership service's profit margin fluctuated significantly, dropping from -24.1% in 2022 to 1.9% in 2024. The online medical service's gross margin decreased to 14.4% in 2023 due to physician compensation issues but rebounded to 16.9% in 2024 [4][5] - The net profit margin has remained negative, with figures of -276.1% in 2022, -79.3% in 2023, and -30.5% in 2024, reflecting weak profitability [6] Revenue Composition - The company's revenue composition is diverse, with health management membership services significantly increasing their share in 2024 and the first half of 2025. This indicates successful development in this area but also highlights a high dependency on a single segment, which poses risks if issues arise in that sector [7][8] Financial Challenges - Despite revenue growth, the company faces financial difficulties, including ongoing losses and high leverage. As of June 30, 2025, the company reported a net debt of approximately 25.3 billion RMB and a net current liability of 25.8 billion RMB, indicating significant leverage pressure [9] - The company relies heavily on three main customer types: local medical insurance funds, corporate clients, and individual users. The largest customer contributed 70.8% of revenue in 2024, increasing to 77.6% in the first half of 2025, which raises concerns about revenue concentration risk [10]

免責聲明 香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出 重大變動。 閣下閱覽本文件，即代表 閣下知悉、接納並向本公司、本公司的保薦人、整體協調人、顧 問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據與香港公司註冊處處長註冊的本公司 招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中 的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、本公司的任何保薦人、整 體協調人、顧問或包銷團成員在香港或任何其他司法權區必須進行發售活動的責任。本公司最終會 否進行發售仍屬未知 ...